Valneva SE, a specialty vaccine company, has signed a new $32.8 million contract with the United States Department of Defense (DoD) for the supply of its Japanese encephalitis (JE) vaccine, IXIARO.

Under the new one-year contract, the DoD will buy a minimum of $32.8 million worth of IXIARO vaccines and has the possibility to purchase additional doses during the coming twelve months. Deliveries of IXIARO doses have continued in 2024 under the supply contract signed in September 2023. The new contract will commence immediately.

IXIARO is the only JE vaccine approved by the U.S. Food and Drug Administration (FDA), having been developed through a cooperative research and development agreement with the Walter Reed Army Institute of Research. In the U.S., Valneva markets and distributes IXIARO directly to the military and private travel market.